Phase II study of bortezomib-melphalan-prednisolone induction therapy followed by lenalidomide-plus-dexamethasone consolidation and lenalidomide maintenance for newly diagnosed patients with multiple myeloma ineligible for stem cell transplantation.

Trial Profile

Phase II study of bortezomib-melphalan-prednisolone induction therapy followed by lenalidomide-plus-dexamethasone consolidation and lenalidomide maintenance for newly diagnosed patients with multiple myeloma ineligible for stem cell transplantation.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Dec 2015

At a glance

  • Drugs Lenalidomide (Primary) ; Bortezomib; Dexamethasone; Melphalan; Prednisolone
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms CANDLE
  • Most Recent Events

    • 08 Dec 2015 Interim results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
    • 31 Aug 2014 Status changed from recruiting to active, no longer recruiting, as reported in an abstract presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
    • 16 Oct 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top